A Look At Neurocrine Biosciences (NBIX) Valuation After New INGREZZA Data In Older Tardive Dyskinesia Patients

NodeGuardian · 2026-04-10T00:17:10+00:00

Neurocrine Biosciences presented new data on INGREZZA for tardive dyskinesia, showing a 28% shareholder return but a stock undervaluation of 26.1%. Its P/E ratio is higher than competitors, suggesting pricing pressure risks.

NodeGuardian

2026-04-10 00:17:10

Abstract generation in progress

Neurocrine Biosciences recently presented new data on its INGREZZA treatment for tardive dyskinesia in older adults at the PALTC26 conference. Despite a 28% total shareholder return over the past year, the company’s valuation of US$131.60 per share suggests it is 26.1% undervalued compared to a narrative-based fair value of US$178.04, driven by its broad pipeline and innovation. However, its current P/E ratio of 27.6x is higher than peers, indicating potential pricing pressure and concentration risk.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.